SCHEMBL3659518

SCHEMBL3659518

NC(=O)CNc1ccc(O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PEPD P12955 1/20 0.54
CA2 P00918 5/20 0.48
ALDH1A1 P00352 4/20 0.44
GAA P10253 3/20 0.44
MAPK1 P28482 3/20 0.44
CA1 P00915 4/20 0.43
BLM P54132 3/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
CYP3A4 P08684 2/20 0.43
HIF1A Q16665 2/20 0.43
CYP1A1 P04798 2/20 0.43
MPO P05164 1/20 0.43
KDM5A P29375 1/20 0.43
GFER P55789 1/20 0.43
PMP22 Q01453 1/20 0.43
CA12 O43570 1/20 0.43
BRD4 O60885 1/20 0.43
NR1I2 O75469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3995569 0.83 ESR1 (0.55) CA2ALDH1A1GAACA1BLM
SCHEMBL11647073 0.83 CA1 (0.41) CA2ALDH1A1CA1MAPTHIF1A
SCHEMBL4572857 0.81 CA12 (0.53) CA2ALDH1A1GAACA1MAPT
SCHEMBL5518500 0.81 ALDH1A1 (0.55) CA2ALDH1A1GAACA1MEN1
Hydrochloric Acid SCHEMBL4804173 0.81 ESR1 (0.54) CA2GAACA1BLMMEN1
SCHEMBL4395547 0.81 NPC1 (0.55) CA2ALDH1A1GAACA1MEN1
SCHEMBL7445665 0.81 MEN1 (0.50) CA2ALDH1A1GAACA1MEN1
SCHEMBL22354 0.80 CYP1A1 (0.52) PEPDCA2ALDH1A1GAAMAPK1
SCHEMBL9745051 0.80 CYP1A1 (0.52) PEPDCA2ALDH1A1GAAMAPK1
Hydrochloric Acid SCHEMBL11326485 0.80 CYP1A1 (0.52) PEPDCA2ALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723882-B1 PROCESS FOR PREPARING 3'-THIOSUBSTITUTED CEPHALOSPORINS EMPLOYING A PENICILLIN G ACYLASE CENTRIENT PHARMACEUTICALS NETHERLANDS B V (NL) 2019-05-01 EP claimed
US-20150112057-A1 NOVEL CRYSTALLINE CEFOPERAZONE INTERMEDIATE DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2015-04-23 US claimed
EP-2723881-A2 NOVEL CRYSTALLINE CEFOPERAZONE INTERMEDIATE DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) 2014-04-30 EP claimed
EP-2723882-A1 PROCESS FOR PREPARING 3'-THIOSUBSTITUTED CEPHALOSPORINS EMPLOYING A PENICILLIN G ACYLASE DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) 2014-04-30 EP claimed
WO-2012175585-A1 PROCESS FOR PREPARING 3'-THIOSUBSTITUTED CEPHALOSPORINS EMPLOYING A PENICILLIN G ACYLASE DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2012-12-27 WO claimed
WO-2012175587-A2 NOVEL CRYSTALLINE CEFOPERAZONE INTERMEDIATE DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2012-12-27 WO claimed
EP-1603549-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS Yu, Ruey J., Dr. (US) 2005-12-14 EP claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
US-20040220264-A1 Bioavailability and improved delivery of acidic pharmaceutical drugs YU RUEY J 2004-11-04 US claimed
WO-2004082628-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS YU RUEY J (US) 2004-09-30 WO claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
EP-0865443-B1 PROCESS FOR THE PREPARATION OF AN ANTIBIOTIC DSM NV (NL) 2003-03-19 EP claimed
WO-2002074266-A2 METHOD AND COMPOSITION FOR THE GRADUAL PERMANENT COLORING OF HAIR UNILEVER PLC (GB) 2002-09-26 WO claimed
EP-0960945-B1 Enzymatic process for producing beta-lactam antibiotics involving product recovery at pH 1 in the presence of immobilized penicillin amidase UNIFAR KIMYA SANAYII VE TICARE (TR) 2002-09-04 EP claimed
EP-1019363-B1 PROCESS FOR THE PREPARATION OF AN INORGANIC SALT OF AN OPTICALLY ACTIVE PHENYLGLYCINE DERIVATIVE DSM NV (NL) 2002-08-28 EP claimed
US-6218138-B1 REACTING AMINO-BETA-LACTAM COMPONENT AND CORRESPONDING AMINO-GROUP CONTAINING ACYLATING SIDE CHAIN COMPONENT IN PRESENCE OF BIOCATALYSTTO FORM ANTIBIOTIC, SOLUBILIZING BY ADDING ACID WHICH DEACTIVATES ENZYME; ENZYME IS REUSEDENZYME UNIFAR KIMYA SANAYI VE TICARET A.S. (TM) 2001-04-17 US claimed
EP-0960945-A2 Enzymatic process for producing beta-lactam antibiotics involving product recovery at pH 1 in the presence of immobilized penicillin amidase Unifar Kimya Sanayii ve Ticaret A.S (TR) 1999-12-01 EP claimed
US-5306826-A Mixing mixture of Schiff bases of amides or amides and aldehyde, solvent, optically active acid, water to form salt, separating diastereomers, converting salt to amide STAMICARBON B.V. (NL) 1994-04-26 US claimed
EP-0442584-B1 Process for the preparation of an optically active amino acid amide DSM NV (NL) 1993-11-10 EP claimed
EP-0442584-A1 Process for the preparation of an optically active amino acid amide DSM N.V. (NL) 1991-08-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150112057-A1 NOVEL CRYSTALLINE CEFOPERAZONE INTERMEDIATE CPN1, PEPD, GLO1 PEPD 2/4885CA2 2272/4885ALDH1A1 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.